Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection
This study has been completed.
Study NCT00782353   Information provided by Hoffmann-La Roche

First Received on October 28, 2008.   Last Updated on November 12, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Hepatitis C
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
ANA598 200 mg bid or placebo
ANA598 400 mg bid or placebo
ANA598 800 mg bid or placebo
Additional drug interventions recognized in this trial
Antiviral Agents
More general drug interventions related to this trial
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Hoffmann-La Roche


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services